| Literature DB >> 28642214 |
Grzegorz Zuk1, Katharina B Reinisch1, Dimitri A Raptis2, Sonia Fertsch3, Merlin Guggenheim4, Adrian F Palma1.
Abstract
BACKGROUND: Dupuytren disease is a chronic nonmalign fibroproliferative disorder that causes finger contractures via proliferation of new tissue under the glabrous skin of the hand, resulting in multiple functional limitations for the patient. As many surgical therapy options exist, patients suffering from this condition actively search for information in their environment before consulting a health professional.Entities:
Keywords: Internet; congenital hand deformity; patient education
Year: 2017 PMID: 28642214 PMCID: PMC5500780 DOI: 10.2196/ijmr.7822
Source DB: PubMed Journal: Interact J Med Res ISSN: 1929-073X
Overall results of the included websites according to the modified Ensuring Quality Information for Patients (EQIP) Instrument.
| Data | Item | Criteria | Yes, n (%) | No, n (%) | Does not |
| 1 | Initial definition of which subjects will be covered | 43 (36.4) | 75 (63.6) | 0 (0) | |
| 2 | Coverage of the previously defined subjects (NAaif the answer is “no” for item 1) | 43 (36.4) | 75 (63.6) | 0 (0) | |
| 3 | Description of the medical problem | 115 (97.5) | 3 (2.5) | 0 (0) | |
| 4 | Definition of the purpose of the surgical intervention | 103 (87.3) | 15 (12.7) | 0 (0) | |
| 5 | Description of treatment alternatives | 86 (72.9) | 32 (27.1) | 0 (0) | |
| 6 | Description of the sequence of the surgical procedure | 59 (50.0) | 59 (50.0) | 0 (0) | |
| 7 | Description of the qualitative benefits to the recipient | 58 (49.2) | 60 (50.8) | 0 (0) | |
| 8 | Description of the quantitative benefits to the recipient | 11 (9.3) | 107 (90.7) | 0 (0) | |
| 9 | Description of the qualitative risks and side effects | 66 (55.9) | 52 (44.1) | 0 (0) | |
| 10 | Description of the quantitative risks and side effects | 23 (19.5) | 95 (80.5) | 0 (0) | |
| 11 | Addressing quality-of-life issues | 64 (54.2) | 54 (45.8) | 0 (0) | |
| 12 | Description of how complications are handled | 10 (8.5) | 108 (91.5) | 0 (0) | |
| 13 | Description of the precautions that the patient may take | 25 (21.2) | 93 (78.8) | 0 (0) | |
| 14 | Mention of alert signs that the patient may detect | 20 (16.9) | 98 (83.1) | 0 (0) | |
| 15 | Addressing medical intervention costs and insurance issues | 9 (7.6) | 109 (92.4) | 0 (0) | |
| 16 | Specific contact details for hospital services | 48 (40.7) | 70 (59.3) | 0 (0) | |
| 17 | Specific details of other sources of reliable | 47 (39.8) | 71 (60.2) | 0 (0) | |
| 18 | Coverage of all relevant issues for the topic (summary item for all content criteria) | 0 (0) | 118 (100) | 0 (0) | |
| 19 | Date of issue or revision | 52 (44.1) | 66 (55.9) | 0 (0) | |
| 20 | Logo of the issuing body | 111 (94.1) | 7 (5.9) | 0 (0) | |
| 21 | Names of the persons or entities that produced the | 37 (31.4) | 81 (68.6) | 0 (0) | |
| 22 | Names of the persons or entities that financed the | 1 (0.8) | 117 (99.2) | 0 (0) | |
| 23 | Short bibliography of the evidence-based data used in the document | 37 (31.4) | 81 (68.6) | 0 (0) | |
| 24 | Statement about whether and how patients were involved or consulted in the document’s production | 51 (43.2) | 67 (56.8) | 0 (0) | |
| 25 | Use of everyday language and explanation of complex words or jargon | 111 (94.1) | 7 (5.9) | 0 (0) | |
| 26 | Use of generic names for all medications or products (NA if no medications described) | 35 (29.7) | 83 (70.3) | 0 (0) | |
| 27 | Use of short sentences (<15 words on average) | 109 (92.4) | 9 (7.6) | 0 (0) | |
| 28 | Personal address to the reader | 33 (28.0) | 85 (72.0) | 0 (0) | |
| 29 | Respectful tone | 118 (100) | 0 (0) | 0 (0) | |
| 30 | Clear information (no ambiguities or contradictions) | 116 (98.3) | 2 (1.7) | 0 (0) | |
| 31 | Balanced information on risks and benefits | 16 (13.6) | 102 (86.4) | 0 (0) | |
| 32 | Presentation of information in a logical order | 115 (97.5) | 3 (2.5) | 0 (0) | |
| 33 | Satisfactory design and layout (excluding figures or graphs) | 91 (77.1) | 27 (22.9) | 0 (0) | |
| 34 | Clear and relevant figures or graphs (NA if absent) | 21 (17.8) | 97 (82.2) | 0 (0) | |
| 35 | Inclusion of a named space for the reader’s note or | 3 (2.5) | 115 (97.5) | 0 (0) | |
| 36 | Inclusion of a printed consent form contrary to | 2 (1.7) | 116 (98.3) | 0 (0) |
aNA: not applicable.
Figure 1Box plot presenting website scoring based on the modified Ensuring Quality Information for Patients (EQIP) tool depending on country of origin. The horizontal thick line within the box plot represents the median. The upper line of the box plot represents the 75th percentile, whereas the lower the 25th percentile. The upper whisker line represents the maximum value, whereas the lower the minimum value. Outliers are shown as circles.
Figure 2Distribution of the total 118 evaluated websites depending on source of information.
Figure 3Box plot presenting website scoring based on the modified Ensuring Quality Information for Patients (EQIP) tool depending on source of information.
Figure 4Histogram presenting the number of websites (Y=vertical axis) and their scores according to the modified Ensuring Quality Information for Patients (EQIP) instrument (X=horizontal axis).
The top rated websites (>95th percentile) according to the modified Ensuring Quality Information for Patients (EQIP).
| Ranking | Website | Country of origin | Source of | Score |
| 1 | http://dupuytrens-society.org/index.html | United Kingdom | Professional society | 28 |
| 1 | http://www.cig0.com/healthwellness/hw/medical-topics/dupuytrens-disease-ue4602 | United States | Professional society | 28 |
| 2 | http://depts.washington.edu/uwhand/Therapy/dupuytrens.php | United States | Academic center | 26 |
| 3 | http://www.emedicinehealth.com/dupuytrens_disease-health/article_em.htm | United States | Professional society | 25 |
| 3 | http://www.nhs.uk/conditions/Dupuytrens-contracture/Pages/Introduction.aspx | United Kingdom | Professional society | 25 |
| 3 | http://www.orthop.washington.edu/?q=patient-care/hand/dupuytrens-disease.html-0 | United States | Academic center | 25 |
Figure 5Scatter plot with the year of website publication on the horizontal axis (X) and their scores awarded by the modified Ensuring Quality Information for Patients (EQIP) instrument on the vertical axis (Y). The solid line represents the mean EQIP score of the websites.